AtaiBeckley Inc. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
4.330
-0.010 (-0.23%)
At close: Apr 28, 2026, 4:00 PM EDT
4.320
-0.010 (-0.23%)
After-hours: Apr 28, 2026, 4:27 PM EDT
AtaiBeckley Revenue
In the year 2025, AtaiBeckley had annual revenue of $4.09M with 1,227.60% growth. AtaiBeckley had revenue of $1.07M in the quarter ending December 31, 2025, a decrease of -21,420.00%.
Revenue (ttm)
$4.09M
Revenue Growth
+1,227.60%
P/S Ratio
381.78
Revenue / Employee
$41,303
Employees
99
Market Cap
1.58B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 868.45M |
| Innoviva | 411.33M |
| AnaptysBio | 234.60M |
| Nurix Therapeutics | 71.78M |
| Vir Biotechnology | 68.56M |
| Intellia Therapeutics | 67.67M |
| Nuvation Bio | 62.90M |
| Generate Biomedicines | 31.89M |
ATAI News
- 1 day ago - AtaiBeckley Transcript: Needham Virtual Psychedelics Forum - Transcripts
- 1 day ago - AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research - GlobeNewsWire
- 6 days ago - AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder - GlobeNewsWire
- 8 days ago - AtaiBeckley Stock Skyrockets As Psychedelic Rally Extends On Trump Fast‑Track Order - Benzinga
- 8 days ago - How Trump's psychedelics executive order could unlock stalled cannabis reform - CNBC
- 8 days ago - Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research - Forbes
- 8 days ago - Psychedelic stocks rally with Trump's support - Market Watch
- 8 days ago - Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring. - Barrons